Antithrombotic Kinetics

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/127

encourage image

There's no tags or description

Looks like no tags are added yet.

128 Terms

1
New cards
Factor II half-life
Approximately 60–100 hours.
2
New cards
Factor VII half-life
Approximately 4–6 hours.
3
New cards
Factor IX half-life
Approximately 20–30 hours.
4
New cards
Factor X half-life
Approximately 24–40 hours.
5
New cards
Protein C half-life
Approximately 6–8 hours.
6
New cards
Protein S half-life
Approximately 40–60 hours.
7
New cards

Warfarin plasma concentration limitation

have a poor relationship with biological effects, so plasma concentrations are not routinely used to guide therapy.

8
New cards
Warfarin dose variability
Response to warfarin varies widely between patients, so dosing must be individualized.
9
New cards
Factors affecting warfarin initial dosing
Medications, indication, age, concurrent illness, and genetic factors.
10
New cards
Patients who generally require lower initial warfarin doses
Elderly, debilitated, malnourished patients and those with CHF, liver disease, recent surgery, or increased sensitivity to warfarin.
11
New cards
Why warfarin doses greater than 10 mg are generally avoided
Increased risk of excessive anticoagulation and development of skin necrosis.
12
New cards
Primary warfarin monitoring test
International Normalized Ratio (INR).
13
New cards
Warfarin outpatient INR monitoring during initiation
Every 2–3 days.
14
New cards
Warfarin INR monitoring after a dose adjustment or new interaction
Every 1–4 weeks.
15
New cards
Warfarin INR monitoring with a stable dose
Every 2–6 weeks.
16
New cards
Warfarin inpatient INR monitoring
Daily.
17
New cards
Warfarin INR monitoring after more than 1 week on a stable inpatient dose
Weekly.
18
New cards
Warfarin Hgb/Hct monitoring
Daily to weekly in hospitalized patients.
19
New cards

what should you monitor daily when on any anticoagulant

signs and symptoms of bleeding and thrombosis.

20
New cards

how much should you adjust doses of warfarin by

small increments of approximately 5–20% of the total weekly dose.

21
New cards
Rifampin + warfarin
Induces warfarin metabolism, causing a gradual or delayed decrease in warfarin effect.
22
New cards
Carbamazepine + warfarin
Induces warfarin metabolism, causing a gradual or delayed decrease in warfarin effect.
23
New cards
Barbiturates + warfarin
Induce warfarin metabolism, causing a gradual or delayed decrease in warfarin effect.
24
New cards
Amiodarone + warfarin
Inhibits warfarin metabolism and increases warfarin effect.
25
New cards
Warfarin adjustment with amiodarone
Empirically decrease the warfarin dose by approximately 50%.
26
New cards
Erythromycin + warfarin
Inhibits warfarin metabolism, producing a quicker increase in warfarin effect.
27
New cards

bile acid sequestriants (Cholestyramine/Colestipol ) + warfarin

Binds warfarin in the GI tract and decreases its absorption.

28
New cards
Sucralfate + warfarin
Binds warfarin in the GI tract and decreases its absorption.
29
New cards
Warfarin timing with cholestyramine, colestipol, or sucralfate
Give warfarin 2 hours before or 6 hours after the interacting drug.
30
New cards
Second- or third-generation cephalosporins + warfarin
Inhibit cyclic interconversion of vitamin K; monitor warfarin more frequently.
31
New cards
Thyroxine + warfarin
Increases metabolism of coagulation factors; monitor warfarin more frequently.
32
New cards
Sulfonamides + warfarin
Eliminate bacterial flora and aggravate vitamin K deficiency; monitor warfarin more frequently.
33
New cards
Broad-spectrum antibiotics + warfarin
Eliminate bacterial flora and aggravate vitamin K deficiency; monitor warfarin more frequently.
34
New cards
St. John's wort + warfarin
Induces warfarin metabolism.
35
New cards
Cranberry juice + warfarin
Inhibits warfarin metabolism according to the lecture.
36
New cards
Grapefruit juice + warfarin
Inhibits warfarin metabolism according to the lecture.
37
New cards
Vitamin K intake + warfarin
Vitamin K intake can alter the patient's response to warfarin and should be considered when dosing.
38
New cards
Sources of vitamin K that should be considered with warfarin
Vegetables, multivitamins, weight-loss plans, and supplements.
39
New cards
Hepatic dysfunction + warfarin
Impaired synthesis of coagulation factors can increase warfarin response and requires more frequent monitoring.
40
New cards
CHF + warfarin
Can impair synthesis of coagulation factors and requires more frequent monitoring.
41
New cards
Hypermetabolic states + warfarin
Increase catabolism of vitamin K-dependent coagulation factors.
42
New cards
GI disease + warfarin
May decrease absorption of fat-soluble vitamin K.
43
New cards
CYP2C9*2 and CYP2C9*3
Alleles associated with impaired ability to metabolize S-warfarin.
44
New cards
VKORC1
Gene associated with hereditary warfarin resistance in some individuals.
45
New cards

UFH drug class

Indirect anticoagulant

46
New cards
UFH molecular weight
Ranges from approximately 3,000–30,000 Daltons, with a mean of about 15,000 Daltons.
47
New cards
UFH structure
Heterogeneous product with a mean of approximately 45 monosaccharide units.
48
New cards
UFH mechanism of action
Binds antithrombin through its pentasaccharide sequence and accelerates antithrombin-mediated inhibition of coagulation factors.
49
New cards
UFH pentasaccharide sequence
Binds antithrombin and causes a conformational change that accelerates its interaction with Factor Xa.
50
New cards
UFH mechanism for thrombin inhibition
Heparin must simultaneously bind antithrombin and thrombin to potentiate thrombin inhibition.
51
New cards
Minimum UFH chain length required for thrombin inhibition
At least 18 saccharide units, approximately 5,400 Da.
52
New cards
UFH Factor Xa inhibition
Binding of the pentasaccharide sequence to antithrombin accelerates Factor Xa inhibition.
53
New cards

UFH use

Treatment of active thrombosis, setting of ACS, prevention of clot formation, prolongation of catheters

54
New cards
UFH routes of administration
IV or subcutaneous.
55
New cards
Subcutaneous UFH bioavailability
Variable; approximately 10–90%.
56
New cards
UFH distribution
Primarily distributed throughout the vascular system.
57
New cards
UFH volume of distribution
Approximately 0.05–0.07 L/kg.
58
New cards
UFH protein binding
More than 50% binds to plasma proteins.
59
New cards
UFH zero-order elimination
Saturable pathway involving metabolism and depolymerization by endothelial cells and macrophages.
60
New cards
UFH first-order elimination
Non-saturable renal clearance.
61
New cards
UFH half-life
Approximately 0.4–2.5 hours.
62
New cards
Factors affecting UFH half-life
Dose, age, thromboembolic disease state, hepatic impairment, renal impairment, and obesity.
63
New cards

what weight is used of UPH dosing

total body weight.

64
New cards
UFH dosing consideration in obesity
Use maximum bolus dose limits to avoid overdosing.
65
New cards
UFH acute VTE loading dose
80 units/kg IV bolus.
66
New cards
UFH acute VTE continuous infusion
18 units/kg/hour.
67
New cards
UFH ACS loading dose
60–70 units/kg.
68
New cards

When is a UFH bolus dose not needed

high bleeding risk, rapid anticoagulation is not needed

69
New cards
Purpose of UFH bolus
Rapidly achieves therapeutic anticoagulation.
70
New cards
UFH aPTT less than 35 seconds
Increase infusion by 4 units/kg/hr, rebolus with 80 units/kg, and repeat aPTT in 6 hours.
71
New cards
UFH aPTT 35–45 seconds
Increase infusion by 2 units/kg/hr, rebolus with 40 units/kg, and repeat aPTT in 6 hours.
72
New cards
UFH aPTT 46–70 seconds
No infusion change, no rebolus, and repeat aPTT in 6 hours.
73
New cards

UFH therapeutic aPTT range

46–70 seconds.

74
New cards
UFH aPTT 71–90 seconds
Decrease infusion by 2 units/kg/hr, do not rebolus, and repeat aPTT in 6 hours.
75
New cards
UFH aPTT greater than 90 seconds
Decrease infusion by 3 units/kg/hr and hold the infusion for 1 hour.
76
New cards
UFH aPTT monitoring during the first 24 hours
Repeat aPTT every 6 hours.
77
New cards
UFH aPTT monitoring after the first 24 hours
Monitor once every morning unless the aPTT is outside the therapeutic range.
78
New cards
UFH ACS/stroke rebolus doses
Use 70 units/kg and 35 units/kg reboluses instead of the VTE 80 units/kg and 40 units/kg reboluses.
79
New cards
UFH continuous infusion monitoring tests
aPTT or anti-Xa.
80
New cards

UFH aPTT or anti-Xa monitoring frequency after initiation

Check 4–8 hours after initiation.

81
New cards

UFH aPTT or anti-Xa monitoring freq after a rate change

Check 4–8 hours after the change.

82
New cards

UFH aPTT or anti-Xa monitoring freq once therapeutic

Every 24 hours.

83
New cards

UFH monitoring freq during extracorporeal circulation

aPTT every 30–60 minutes.

84
New cards

Why are platelets monitored in patients receiving UFH

possibility of developing heparin-induced thrombocytopenia with thrombosis (HITT).

85
New cards

Why is Hgb/Hct monitored in patients receiving UFH

decreases may be early indicators of bleeding.

86
New cards

Heparin patients should monitor what daily

signs and symptoms of bleeding or thrombosis.

87
New cards

LMWH is derived from what

from unfractionated heparin.

88
New cards
LMWH molecular weight
Approximately 4,000–5,000 Daltons.
89
New cards

LMWH size compared with UFH

Approximately one-third the molecular weight

90
New cards
Dalteparin brand name
Fragmin.
91
New cards
Enoxaparin brand name
Lovenox.
92
New cards
Tinzaparin brand name
Innohep.
93
New cards
Why LMWH products have different properties
Different depolymerization methods produce differences in pharmacokinetic properties, anticoagulant profiles, and recommended dosing regimens.
94
New cards
LMWH mechanism of action
Catalyzes antithrombin-mediated inhibition of coagulation factors.
95
New cards
LMWH ability to inactivate thrombin compared with UFH
Reduced because the smaller fragments cannot simultaneously bind antithrombin and thrombin.
96
New cards

LMWH pentasaccharide-containing sequence is required for what

antithrombin binding (found on less than one-third of LMWH molecules)

97
New cards
LMWH route of administration
Subcutaneous.
98
New cards
LMWH subcutaneous bioavailability
Approximately 90%.
99
New cards
LMWH elimination half-life
Approximately 3–6 hours after injection.
100
New cards
LMWH half-life relationship to dose
Elimination half-life is dose-independent.